A small study testing the pharmacodynamic effects of several antiplatelet agents suggests that tirofiban (Aggrastat; Medicure), a glycoprotein IIb/IIIa inhibitor, may provide “more potent and ...
Please provide your email address to receive an email when new articles are posted on . The study, which was presented at the virtual PCR e-Course and simultaneously published in Circulation, also ...
To evaluate the in vivo impact of ibrutinib on platelet aggregation, we performed LTA testing in subjects receiving stable ibrutinib therapy. Human Ethics Research Committee approved platelet studies ...
AGGREGATION of platelets in the presence of adenosine diphosphate (ADP) appears to be important in hæmostasis and in the genesis of platelet thrombosis. There is evidence that this reaction is common ...
Background PRAGUE-8: Duration of Clopidogrel Before Elective Angiography vs Before Percutaneous Coronary Intervention Platelet Aggregation: Prasugrel vs Clopidogrel in Aspirin-treated Patients ...
Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container. Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container.
Objective: To review and assess available literature on thechemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical studies, adverse events, drug interactions, special populations, and ...
When cancer cells and platelets mix, the risk of metastasis and cancer-related deep vein thrombosis (DVT) and pulmonary embolism (PE) increases, but a small, proof-of-concept study suggests that the ...
Please provide your email address to receive an email when new articles are posted on . A higher dose of a glycoprotein VI inhibitor in patients with CAD who underwent PCI resulted in more pronounced ...
SAN DIEGO--(BUSINESS WIRE)--CeleCor Therapeutics, Inc. today announced preliminary positive results in the company’s ongoing phase 1 clinical study with RUC-4, a novel subcutaneous platelet GPIIb/IIIa ...
SAN DIEGO--(BUSINESS WIRE)--CeleCor Therapeutics, Inc. announced positive data from the company’s completed phase 1 clinical study of RUC-4 which was published in the Journal of the American Heart ...
A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results